Nuance Investments LLC cut its stake in shares of Globe Life Inc. (NYSE:GL - Free Report) by 55.1% in the 1st quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 554,521 shares of the company's stock after selling 679,548 shares during the period. Globe Life accounts for 4.8% of Nuance Investments LLC's holdings, making the stock its 6th largest position. Nuance Investments LLC owned about 0.67% of Globe Life worth $73,042,000 as of its most recent filing with the Securities & Exchange Commission.
Other hedge funds have also recently bought and sold shares of the company. SouthState Corp acquired a new position in shares of Globe Life in the first quarter valued at about $43,000. Allworth Financial LP boosted its holdings in Globe Life by 22.0% in the 1st quarter. Allworth Financial LP now owns 571 shares of the company's stock valued at $71,000 after purchasing an additional 103 shares during the period. Versant Capital Management Inc grew its position in shares of Globe Life by 140.2% during the 1st quarter. Versant Capital Management Inc now owns 586 shares of the company's stock worth $77,000 after purchasing an additional 342 shares in the last quarter. Blue Trust Inc. increased its holdings in shares of Globe Life by 42.4% during the first quarter. Blue Trust Inc. now owns 772 shares of the company's stock worth $102,000 after purchasing an additional 230 shares during the period. Finally, Virtus Fund Advisers LLC acquired a new stake in shares of Globe Life in the fourth quarter valued at approximately $116,000. 81.61% of the stock is currently owned by institutional investors and hedge funds.
Analysts Set New Price Targets
A number of brokerages recently issued reports on GL. Wall Street Zen raised Globe Life from a "hold" rating to a "buy" rating in a research report on Friday, May 16th. BMO Capital Markets restated a "market perform" rating and issued a $149.00 price target (up previously from $114.00) on shares of Globe Life in a research report on Wednesday, July 30th. JPMorgan Chase & Co. upped their price objective on shares of Globe Life from $145.00 to $160.00 and gave the stock an "overweight" rating in a research report on Tuesday, July 8th. Keefe, Bruyette & Woods raised their target price on shares of Globe Life from $145.00 to $155.00 and gave the company an "outperform" rating in a report on Monday, July 28th. Finally, Wells Fargo & Company upped their price target on shares of Globe Life from $144.00 to $150.00 and gave the stock an "overweight" rating in a report on Friday, July 25th. Two analysts have rated the stock with a hold rating, nine have issued a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat, the stock currently has a consensus rating of "Moderate Buy" and an average price target of $152.00.
Check Out Our Latest Report on Globe Life
Insider Transactions at Globe Life
In other news, CEO James Matthew Darden sold 33,270 shares of the firm's stock in a transaction on Friday, July 25th. The shares were sold at an average price of $135.59, for a total transaction of $4,511,079.30. Following the completion of the transaction, the chief executive officer owned 49,842 shares of the company's stock, valued at approximately $6,758,076.78. This trade represents a 40.03% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CEO Frank M. Svoboda sold 12,500 shares of Globe Life stock in a transaction on Thursday, July 31st. The stock was sold at an average price of $141.38, for a total transaction of $1,767,250.00. Following the transaction, the chief executive officer owned 32,747 shares in the company, valued at approximately $4,629,770.86. This trade represents a 27.63% decrease in their position. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 90,741 shares of company stock worth $12,471,180. 1.97% of the stock is owned by corporate insiders.
Globe Life Price Performance
Shares of NYSE:GL opened at $139.01 on Tuesday. The firm has a 50 day simple moving average of $125.62 and a 200 day simple moving average of $123.88. The company has a market cap of $11.26 billion, a price-to-earnings ratio of 11.11 and a beta of 0.56. Globe Life Inc. has a one year low of $91.26 and a one year high of $144.00. The company has a debt-to-equity ratio of 0.43, a current ratio of 0.06 and a quick ratio of 0.06.
Globe Life (NYSE:GL - Get Free Report) last announced its quarterly earnings results on Wednesday, July 23rd. The company reported $3.27 EPS for the quarter, beating analysts' consensus estimates of $3.25 by $0.02. The company had revenue of $1.48 billion during the quarter, compared to analysts' expectations of $1.50 billion. Globe Life had a return on equity of 21.24% and a net margin of 18.11%. Globe Life's revenue was up 2.9% compared to the same quarter last year. During the same period in the prior year, the company earned $2.97 EPS. Research analysts predict that Globe Life Inc. will post 13.87 earnings per share for the current fiscal year.
Globe Life Announces Dividend
The company also recently disclosed a quarterly dividend, which will be paid on Friday, October 31st. Stockholders of record on Friday, October 3rd will be paid a $0.27 dividend. The ex-dividend date of this dividend is Friday, October 3rd. This represents a $1.08 annualized dividend and a dividend yield of 0.8%. Globe Life's dividend payout ratio is currently 8.63%.
Globe Life Company Profile
(
Free Report)
Globe Life Inc, through its subsidiaries, provides various life and supplemental health insurance products, and annuities to lower middle- and middle-income families in the United States. The company operates in four segments: Life Insurance, Supplemental Health Insurance, Annuities, and Investments.
Featured Articles

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Globe Life, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Globe Life wasn't on the list.
While Globe Life currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Wondering what the next stocks will be that hit it big, with solid fundamentals? Enter your email address to see which stocks MarketBeat analysts could become the next blockbuster growth stocks.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.